ClinicalTrials.gg
RecruitingNCT06927310Updated Mar 11, 2026

The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature

A Phase 3 interventional study of Inpegsomatropin Injection and Recombinant Human Growth Hormone Injection in Idiopathic Short Stature, sponsored by Xiamen Amoytop Biotech Co., Ltd.. Recruiting at 38 sites in China. Open to participants aged 3 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by Xiamen Amoytop Biotech Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
3 Years to 11 Years
Sex
All
01

Study summary

This is a multicenter, randomized, open-label, active-controlled Phase III clinical trial to evaluate the efficacy and safety of Inpegsomatropin injection,once a week,compared with recombinant human growth hormone (rhGH) in children with idiopathic short stature (ISS). It plans to enroll 300 children with ISS, who will be randomized , stratified by gender and age, and assigned to either the experimental group or the positive controlled group. Each participant will undergo a screening period (up to 12 weeks), a treatment period (52 weeks), and a post-treatment follow-up period (5 weeks). And the safety and efficacy will be evaluated.

02

Conditions studied

  • Idiopathic Short Stature

Keywords

  • Inpegsomatropin Injection
  • Recombinant Human Growth Hormone Injection
03

In context

Lead sponsor

Xiamen Amoytop Biotech Co., Ltd. is the lead sponsor of 32 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Prepubertal children: boys aged ≥3 years and \<11 years at screening with testicular volume \<4 mL; girls aged ≥3 years and \<10 years at screening with breast development at Tanner Stage I, i.e., no palpable breast glandular tissue.
  • Compared to chronological age, bone age is advanced by no more than 1 year or delayed by no more than 2 years (i.e., -2 years ≤ bone age - chronological age ≤ 1 year).
  • Height at screening is below -2 standard deviations (SD) from the mean for age and sex, with height reference to Appendix 1.
  • (BMI) is within the 5th to 95th percentile for age and sex of healthy children, with reference to Appendix 2.
  • Peak GH level ≥10.0 ng/ml in at least one GH stimulation test.
  • No prior systemic pharmacological treatment for growth promotion (continuous use ≥1 month), including but not limited to growth hormone, insulin-like growth factor 1 (IGF-1), etc.
  • The legal guardian understands and signs the form. If the participants is ≥8 years old, they must also sign the informed consent form. For participants under 8 years old who are able to express their consent, their assent should be clearly documented.

Exclusion criteria

Exclusion Criteria:

  • Individuals with closed epiphyses;
  • Other types of growth and developmental abnormalities, including confirmed or highly suspected growth hormone deficiency (GHD), Noonan syndrome, Prader-Willi syndrome, Russell-Silver syndrome, Turner syndrome, small for gestational age, short stature due to SHOX gene abnormalities, growth delay due to malnutrition, growth delay due to hypothyroidism, and other short statures with a clear etiology; genetic testing results must be obtained before randomization to exclude short stature caused by definite genetic abnormalities;
  • Individuals who have participated in any other clinical trial within 3 months prior to screening and have received pharmacological or non-pharmacological interventions;
  • Individuals who received inhaled for more than 2 consecutive weeks, or oral or intravenous corticosteroids for more than 1 consecutive week, within the 3 months prior to screening;
  • Individuals who are currently receiving or require long-term treatment with other therapies that may affect growth, including but not limited to methylphenidate, sex hormones, gonadotropin-releasing hormone analogs, aromatase inhibitors, anabolic agents, insulin, etc.;
  • Individuals with abnormal liver or kidney function at screening ( > 1.5 times the , Cr > upper limit of normal);
  • Individuals diagnosed with diabetes mellitus, or with fasting blood glucose ≥6.1 mmol/L on two consecutive occasions;
  • Individuals with chronic infectious diseases, such as chronic ;
  • Individuals with systemic chronic diseases, such as moderate to severe anemia, malnutrition, hypothyroidism, chronic kidney disease, cardiovascular diseases (e.g., dilated cardiomyopathy, etc.), psychiatric and psychological disorders, or those with congenital anomalies requiring clinical intervention as determined by the investigator;
  • Individuals with congenital skeletal abnormalities, or those with scoliosis exceeding 15°, limping, or a history of slipped capital femoral epiphysis;
  • Individuals with a history of increased intracranial pressure;
  • Individuals with a history of or currently having active malignancy, including intracranial tumors;
  • Individuals with severe allergic constitutions, or known allergies to growth hormone or its ;
  • Individuals with any other disease that the investigator deems may endanger the subject's safety or compromise compliance with the study protocol.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Inpegsomatropin group

    Drug: Inpegsomatropin Injection

  • Active comparator
    rhGH group

    Drug: Recombinant Human Growth Hormone Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Growth velocity (HV, cm/year).

    Time frame: Week 52

Secondary outcomes

  1. Change in height standard deviation score from baseline (△HT SDS)

    Time frame: From baseline to all follow-up time points at Week 52

  2. Change in growth velocity from baseline (△HV)

    Time frame: From baseline to all follow-up time points at Week 52

  3. Change in insulin-like growth factor 1 standard deviation score from baseline (△IGF-1 SDS)

    Time frame: From baseline to all follow-up time points at Week 52

  4. The ratio of the change in bone age to the change in chronological age (△BA/△CA)

    Time frame: From baseline to all follow-up time points at Week 52

07

Study locations

38 of 38 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Mar 2026, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2025
First posted
Apr 15, 2025
StartActual
Apr 28, 2025
Primary completionEst.
Mar 2026
CompletionEst.
Jun 2028
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06927310
Collaborators
Tongji Hospital
Responsible party
Sponsor
First posted
Apr 15, 2025
Start date
Apr 28, 2025
Primary completion
Mar 2026 (estimated)
Completion
Jun 2028 (estimated)
Last update
Mar 11, 2026

Study contacts

Xiaoping Luo, Ph.D
Contact
xpluo@tjh.tjmu.edu.cn
15671671188
Xiaoping Luo, Ph.D
principal investigator · Tongji Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inpegsomatropin

Start the discussion